Searched for
PHARMA SHARES
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...- Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- How Sensex, Nifty rallied 200% under PM Modi's record-breaking tenureIndian equity markets delivered strong long-term returns during Prime Minister Narendra Modi’s tenure, with the Sensex and Nifty gaining ar...
- Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and ...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Diversity hiring jumps 21% despite slowdown in white-collar recruitment: founditWhite-collar hiring in India saw a slowdown in May 2026. However, diversity hiring experienced a substantial surge. This trend highlights a...
- Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata MotorsIndian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...
- Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- India-Oman CEPA kicks in June 1: What gets cheaper, which sectors gain, and key benefits explainedIndia's Comprehensive Economic Partnership Agreement with Oman comes into effect on June 1, granting New Delhi 100% duty-free access for 98...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoYNatco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins an...
Load More
